Drugs / AT03-65
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06809114 | Jan 2026 → Dec 2027 expected | cancer | Axcynsis Therapeutics Pte Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-01-15 | Axcynsis Therapeutics Pte Ltd | Regulatory Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology axcynsis.com ↗
Axcynsis Therapeutics Pte Ltd (“Axcynsis”), a privately held biopharmaceutical company specialized in delivering Antibody Drug Conjugates (ADCs) with breakthrough potential, proudly announces the clearance of its Investigational New Drug application (IND) by the United States Food and Drug Administration (FDA) of AT03-65 for the treatment of patients with CLDN-6 positive solid tumors. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-01-15 | Axcynsis Therapeutics Pte Ltd | Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology axcynsis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT03-65 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06809114 ↗ |
| Modality | Other / unclassified | “AT03-65 Antibody Drug Conjugate” NCT06809114 ↗ |
| Route | Intravenous | “Subjects will receive AT03-65 via intravenous (IV) infusion on Day 1 of a 21-Day treatment cycle.” NCT06809114 ↗ |